Biotech News
Related news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-10-29 12:00 EST
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
ABEOAbeona Therapeutics2026-11-02 12:46 EST
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPTSarepta Therapeutics2026-09-30 20:30 EST
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MXCTMaxCyte2026-09-11 20:30 EST
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TSHATaysha Gene Therapies2026-11-06 13:00 EST
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EDITEditas Medicine2026-09-09 13:00 EST
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CRSPCRISPR Therapeutics2026-11-04 14:01 EST
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
CRSPCRISPR Therapeutics2026-11-02 13:00 EST
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-11-06 21:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-11-05 13:00 EST
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-11-04 13:00 EST
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
NTLAIntellia2026-11-03 13:00 EST
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
NTLAIntellia2026-10-29 12:00 EST
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
Stock data
- Close
- 11.10 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States